Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of UGN-104 in low-grade upper tract urothelial cancer
2024-519343-15-00Phase 3Authorised
- Sponsor
- UroGen Pharma
- Start
- Oct 2025
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of Mitomycin C RTGel in upper tract urothelial carcinoma (UTUC), sponsored by UroGen Pharma. Primary endpoint: Complete response rate at primary disease evaluation. Planned start Oct 2025; status: authorised.
02
Drugs
Mitomycin C RTGel
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2024-519343-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519343-15-00.